Home » Diabetes Overview Articles » Clinical trials to stop the progression of type 2 diabetes

About Ravi Retnakaran MD MSc FRCPC and Haysook Choi

Dr. Ravi Retnakaran is a Professor of Medicine at the University of Toronto and an endocrinologist and clinician-scientist at Mount Sinai Hospital in Toronto, Canada. His research program focuses on the pathophysiology and treatment of type 2 diabetes (T2DM), with a particular interest in the potential reversibility of pancreatic beta-cell dysfunction early in the course of diabetes. In this context, his research group is conducting a series of innovative clinical trials evaluating novel therapeutic strategies for the preservation of beta-cell function in early T2DM, including the CIHR-funded RESET IT Trial and PREVAIL Trial. Haysook Choi is a Registered Nurse and Certified Diabetes Educator with over 25 years of experience in the field of diabetes management. She is presently working as a clinical research nurse coordinator at the Leadership Sinai Centre for Diabetes in Toronto. Currently her focus is on the RESET IT trial that is evaluating novel strategies for preservation of beta-cell function and thereby maintaining remission of Type 2 Diabetes.

Check Also

Trials in type 2 diabetes

Landmark trials in type 2 diabetes

As with my previous blog on landmark type 1 diabetes studies, recommendations for the management of type 2 diabetes are also based on evidence from large randomized clinical trials.